The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies - PubMed
Review
doi: 10.1111/odi.12206. Epub 2013 Dec 23.
Affiliations
- PMID: 24219320
- DOI: 10.1111/odi.12206
Free article
Review
The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies
R Vander Broek et al. Oral Dis. 2015 Oct.
Free article
Abstract
Head and neck squamous cell carcinoma (HNSCC) is one of the most morbid, mortal, and genetically diverse malignancies. Although HNSCC is heterogeneous in nature, alterations in major components of the PI3K/Akt/mTOR pathway are consistently observed throughout the majority of HNSCC cases. These alterations include genetic aberrations, such as mutations or DNA copy number variations, and dysregulation of mRNA or protein expression. In normal physiology, the PI3K/Akt/mTOR axis regulates cell survival, growth, and metabolism. However, alterations in this pathway lead to the malignant phenotype which characterizes HNSCC, among many other cancers. For this reason, both pharmaceutical companies and academic institutions are actively developing and investigating inhibitors of PI3K, Akt, and mTOR in preclinical and clinical studies of HNSCC. Many of these inhibitors have shown promise, while the effects of others are tempered by the mechanisms through which HNSCC can evade therapy. As such, current research aimed at elucidating the interactions between PI3K/Akt/mTOR and other important signaling pathways which may drive resistance in HNSCC, such as p53, NF-κB, and MAPK, has become a prominent focus toward better understanding how to most effectively treat HNSCC.
Keywords: Akt; NF-κB; PI3K; head and neck cancer; mTOR; p53.
Published 2013. This article is a US Government work and is in the public domain in the USA.
Similar articles
-
Li Z, Yang Z, Passaniti A, Lapidus RG, Liu X, Cullen KJ, Dan HC. Li Z, et al. Oncotarget. 2016 May 31;7(22):31892-906. doi: 10.18632/oncotarget.7441. Oncotarget. 2016. PMID: 26895469 Free PMC article.
-
PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
Marquard FE, Jücker M. Marquard FE, et al. Biochem Pharmacol. 2020 Feb;172:113729. doi: 10.1016/j.bcp.2019.113729. Epub 2019 Nov 27. Biochem Pharmacol. 2020. PMID: 31785230 Review.
-
Freudlsperger C, Burnett JR, Friedman JA, Kannabiran VR, Chen Z, Van Waes C. Freudlsperger C, et al. Expert Opin Ther Targets. 2011 Jan;15(1):63-74. doi: 10.1517/14728222.2011.541440. Epub 2010 Nov 26. Expert Opin Ther Targets. 2011. PMID: 21110697 Free PMC article. Review.
-
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J Jr, Janku F. Polivka J Jr, et al. Pharmacol Ther. 2014 May;142(2):164-75. doi: 10.1016/j.pharmthera.2013.12.004. Epub 2013 Dec 9. Pharmacol Ther. 2014. PMID: 24333502 Review.
-
Su YC, Lee WC, Wang CC, Yeh SA, Chen WH, Chen PJ. Su YC, et al. Int J Mol Sci. 2022 Dec 12;23(24):15749. doi: 10.3390/ijms232415749. Int J Mol Sci. 2022. PMID: 36555391 Free PMC article. Review.
Cited by
-
The impact of ERP29 on the progression of pharyngeal squamous cell carcinoma.
Carron J, Coser LO, Lima CSP, Lourenço GJ. Carron J, et al. Sci Rep. 2024 Oct 27;14(1):25681. doi: 10.1038/s41598-024-76210-6. Sci Rep. 2024. PMID: 39465248 Free PMC article.
-
Targeting PI3K/AKT/mTOR and MAPK Signaling Pathways in Gastric Cancer.
Morgos DT, Stefani C, Miricescu D, Greabu M, Stanciu S, Nica S, Stanescu-Spinu II, Balan DG, Balcangiu-Stroescu AE, Coculescu EC, Georgescu DE, Nica RI. Morgos DT, et al. Int J Mol Sci. 2024 Feb 3;25(3):1848. doi: 10.3390/ijms25031848. Int J Mol Sci. 2024. PMID: 38339127 Free PMC article. Review.
-
Saintigny P, Mitani Y, Pytynia KB, Ferrarotto R, Roberts DB, Weber RS, Kies MS, Maity SN, Lin SH, El-Naggar AK. Saintigny P, et al. Cancer. 2018 Sep 15;124(18):3693-3705. doi: 10.1002/cncr.31600. Epub 2018 Oct 5. Cancer. 2018. PMID: 30289966 Free PMC article.
-
Chen X, Cao Y, Sedhom W, Lu L, Liu Y, Wang H, Oka M, Bornstein S, Said S, Song J, Lu SL. Chen X, et al. Mol Oncol. 2020 Jan;14(1):139-158. doi: 10.1002/1878-0261.12584. Epub 2019 Oct 26. Mol Oncol. 2020. PMID: 31600013 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous